Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 89, Issue 3, 2000, Pages 299-304

  Patton, Lauren L ^a,e   McKaig, Rosemary ^a   Strauss, Ronald ^b,c   Rogers, Dawn ^d   Eron Jr , Joseph J ^c  

^a Department of Dental Ecology ^*  (United States)

^b Institute for Molecular Virology   (United States)

^c West Indies

^d School of Nursing and Mailman

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; AIDS RELATED COMPLEX; APHTHOUS STOMATITIS; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEUKOPLAKIA; MALE; MIDDLE AGED; MOUTH DISEASE; MOUTH TUMOR; NECROSIS; PERIODONTAL DISEASE; PREVALENCE; SALIVARY GLAND DISEASE; STOMATITIS; THRUSH; TIME; UNITED STATES; VERRUCA VULGARIS;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDIASIS, ORAL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEUKOPLAKIA, HAIRY; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH NEOPLASMS; NECROSIS; NORTH CAROLINA; PERIODONTAL DISEASES; PREVALENCE; SALIVARY GLAND DISEASES; SARCOMA, KAPOSI; STOMATITIS, APHTHOUS; STOMATITIS, HERPETIC; TIME FACTORS; WARTS;

EID: 0034146621     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2000.103530     Document Type: Article

References (50)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Hogg RS, Heath KV, Yip B, Craig KJ, O'Shaughnessy MV, Schlechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
3. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Br Med J 1997;315:1194-9.
4. Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:376-81.
5. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-8.
6. Fleming PL, Ward JW, Karon JM, Hanson DL, De Cock KM. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998;12:555-61.
7. Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998;12:S157-63.
8. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30.
9. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998;280:72-7.
10. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immuno-deficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
11. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
12. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-53.
13. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
14. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations, of the International AIDS Society - USA Panel. JAMA 1998;280:78-86.
15. Centers for Disease Control. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):1-82.
16. Greenspan JS, Barr CE, Sciubba JJ, Winkler JR. Oral manifestations of HIV infection. Definitions, diagnostic criteria, and principles of therapy. Oral Surg Oral Med Oral Pathol 1992;73:142-4.
17. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993;22:289-91.
18. Centers for Disease Control. 1993 Revised classification system for HTV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19.
19. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, Mc Mahon D, et al. Simultaneous vs sequential initiation of therapy with indinavir. zidovudine, and lamivudine for HIV-1 infection. 100-week follow-up. JAMA 1998;280:35-41.
20. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, Me Mahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretriviral therapy. N Engl J Med 1997;337:734-9.
21. Haverkos HW, Turner JF, Moolchan ET, Cadet J-L. Relative rates of AIDS among racial/ethnic groups by exposure categories. J Natl Med Assoc 1999;91:17-24.
22. Centers for Disease Control. AIDS among racial/ethnic minorities-United States, 1993. MMWR 1994;43:644-7, 653-5.
23. McKaig RG, Thomas JC, Patton LL, Strauss RP, Slade GD, Beck JD. Prevalence of HIV-associated periodontitis and chronic periodontitis in a southeastern US study group. J Pub Health Dent 1998;58:294-300.
24. Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:318-26.
25. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
26. Foudraine NA, Hovenkamp E, Notermans DW, Meenhorst PL, Klein MR, Lange JM, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999;13:177-84.
27. Glick M, Muzyka BC, Lurie D, Salkin LM. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994;77:344-9.
28. Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadessa V. HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med 1999;28:173-7.
29. Greenspan JS, Greenspan D, Lennette ET, Abrams KI, Conant MA, Petersen V, et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 1985;313:1564-71.
30. Patton LL, McKaig RG, Strauss RP, Lawrence HP, Eron JJ Jr. Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. AIDS. 1999;13:2174-6.
31. Greenspan JS, Greenspan D. Oral hairy leukoplakia: diagnosis and management. Oral Surg Oral Med Oral Pathol 1989;67:396-403.
32. Resnick L, Herbst JS, Ablashi DV, Atherton S, Frank B, Rosen L, et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 1988;259:384-8.
33. Newman C, Polk F. Resolution of oral hairy leukoplakia during therapy with 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG). Ann Intern Med 1987;107:348-50.
34. Albrecht H, Stellbrink HJ, Brewster D, Greten H. Resolution of oral hairy leukoplakia during treatment with foscarnet. AIDS 1994;8:1014-6.
35. Phelan JA, Klein RS. Resolution of oral hairy leukoplakia during treatment with azidothymidine. Oral Surg Oral Med Oral Pathol 1988;65:717-20.
36. Kessler HA, Benson CH, Urbanski P. Regression of oral hairy leukoplakia during zidovudine therapy. Arch Intern Med 1988;148:2496-7.
37. Arendorf TM, Bredekamp B, Cloete C, Wood R, O'Keefe E. Intergroup comparisons of oral lesions in HIV-positive South Africans. Oral Dis 1997;3:S54-7.
38. Patton LL, McKaig RG, Strauss RP, Eron JJ Jr. Oral manifestations of HIV in a southeast USA population. Oral Dis 1998;4:164-9.
39. Gabrilovich DI, Kozhich AT, Suvorova ZK, Ivanov VS, Moshnikov SA, Chikin LD, et al. Influence of HIV antigens on functional activity of neutrophilic granulocytes in patients with HIV infection. Scand J Immunol 1991;33:549-52.
40. Diz Dios P, Ocampo A, Miralles C, Otero I, Iglesias I, Rayo N. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:437-41.
41. Tozzi V, Narcisco P, Sebastiani D, Frigiotti D, D'Amato C. Effects of indinavir treatment on platelet and neutrophil counts in patients with advanced HIV disease. AIDS 1997;11:1067-8.
42. Patton LL. Hematologic abnormalities among HIV-infected patients: associations of significance for dentistry. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:561-7.
43. Schøidt M, Greenspan D, Daniels TE, Nelson J, Leggott PJ, Wara DW, et al. Parotid gland enlargement with xerostomia associated labial sialadenitis in HIV-infected patients. J Autoimmun 1989;2:415-25.
44. Itescu S, Dalton J, Zhang H-Z, Winchester R. Tissue infiltration in a CD8 lymphocytosis syndrome associated HIV-1 infection has the phenotypic appearance of an antigenically driven response. J Clin Invest 1993;91:2216-25.
45. Hood S, Bonington A, Evans J, Dennis D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998;12:447-8.
46. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr Hum Retrovirol 1999;21:20-5.
47. Greenspan D, Canchola AJ, Macphail LA, Cheikh B, Sroussi H, Palefsky JM, et al. Emergence of oral warts in the HAART era [abstract no. 704]. Conference on retroviruses and opportunistic infections 1999.
48. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998;12:1459-64.
49. Duerr A, Shah K, Schuman P, Klein RS, Cu-uvin S. The effect of highly active antiretroviral therapy (HAART) on cervical dysplasia and HPV infection among HIV-infected women [abstract no. 60289]. Int conf AIDS 1998;12:1052.
50. Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:474-80.